DIRS.INFO The most relevant business & tech news

☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
▼ + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.

Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S

☆ Friday's analyst calls: Goldman raises Nvidia target, JPMorgan upgrades Ferrari
▼ + stars: | 2024-10-11 | by ( Hakyung Kim | In Hakyungkim | ) www.cnbc.com time to read: +4 min

(This is CNBC Pro's live coverage of Thursday's analyst calls and Wall Street chatter. Ferrari's scarcity-driven growth strategy has contributed to price growth of as much as 30% for new vehicles compared to prior vehicles, per Brinkman. — Hakyung Kim 6:25 a.m. Morgan Stanley raises Eli Lilly estimates Morgan Stanley notched its price target for Eli Lilly shares higher on increased weight-loss drug estimates. — Hakyung Kim 6:00: am Goldman Sachs raises Nvidia price target Goldman Sachs believes strong demand for artificial intelligence compute should help drive Nvidia shares higher. Analyst Toshiya Hari increased his price target on Nvidia shares to $150 from $135, implying 11.3% upside potential from Thursday's close.

Persons: Goldman, Morgan Stanley, Elli Lilly, Ryan Brinkman, Brinkman, Ferrari, — Hakyung Kim, Eli Lilly, Terence Flynn, Zepbound, Eli Lilly's, Mounjaro, Flynn, Mercado, Gonzalo Lopez, Lopez, Mercado Credito, Goldman Sachs, Toshiya Hari, Hari, Hakyung Kim Organizations: CNBC, Nvidia, JPMorgan, Ferrari, Mercado Libre, company's Data Locations: Thursday's, Latin America, U.S, America, verticals, Hari

☆ These China stocks are favored by analysts no matter how the central bank stimulus pans out
▼ + stars: | 2024-09-26 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +3 min

Stocks in China rose in response, with the CSI 300 Index climbing 4.3% Tuesday, its best day since July 2020. But whether or not the latest policy steps succeed, CNBC Pro screened for China stocks that analysts praise regardless of the pace of economic growth at home. About three quarters of analysts covering PDD rate it a buy, and the stock could climb roughly 43% based on analysts' consensus price target. On Tuesday, after the announcement of the latest policies to revive the flagging China economy, PDD shares in the U.S. jumped more than 11%. Other names on the list of favored China stocks included online learning and tutoring provider TAL Education Group and digital shipping platform Full Truck Alliance .

Persons: Hong, Morgan Stanley, Terence Flynn, Flynn, CoreValues, Ben Harburg, CNBC's, Harburg, Biden Organizations: People's Bank of China, CSI, CNBC Pro, China ETF, Therapeutics, YE25, U.S, TAL Education Group, Alliance Locations: China, Ph3, U.S

☆ Morgan Stanley analysts give their favorite stocks to own for the next 12 months
▼ + stars: | 2024-09-13 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

From e-commerce firm Amazon to pharmaceutical giant Eli Lilly , Morgan Stanley's top stocks to own for the next 12 months spans a wide array of sectors. The majority of Morgan Stanley's picks are tilted toward growth, with 67% of the picks meeting that classification. Here's a look at some of the stocks that Morgan Stanley says are worth owning over the next year. Amazon stock has added 23% in 2024. LLY YTD mountain Eli Lilly stock.

Persons: Eli Lilly, Morgan, Morgan Stanley's, Morgan Stanley, Brian Nowak's, Nowak, Terence Flynn's, Eli Lilly's, LLY, Flynn Organizations: Nasdaq, Dow Jones, Amazon, Pharma

☆ Morgan Stanley ponders if Eli Lilly could be the first $1 trillion pharma stock on weight loss boom
▼ + stars: | 2024-02-16 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +3 min

On Friday, Flynn raised his price target on Lilly shares to $950 from $805. With Lilly's stock closing Thursday at $757.78, the target suggests 25% more upside ahead. LLY 1Y mountain Eli Lilly shares over the past year. "LLY is establishing high barriers to entry in the diabesity market," Flynn said, adding that this is what contributes to its higher valuation. Phase 3 data is expected on orforglipron in 2025, which Flynn sees as a catalyst for the stock to go higher.

Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Flynn, Lilly, Mounjaro, — CNBC's Michael Bloom Organizations: Novo Nordisk Locations: diabesity

☆ Pharma and rideshare providers are among most overbought S&P 500 stocks this week
▼ + stars: | 2024-02-16 | by ( Alex Harring | ) www.cnbc.com time to read: +5 min

Despite the market's lack of direction this week, investors nonetheless poured into some specific stocks, pushing them into overbought territory. The RSI, which measures the magnitude and speed of price moves, is a popular yardstick used to evaluate whether shares are overbought or oversold. A stock with a 14-day RSI above 70 is considered overbought, signaling a possible selling opportunity. Biogen is another stock on the list that took a sizable drop this week, with shares tumbling more than 7%. But Wall Street anticipates a turnaround, with the consensus price target reflecting the potential for upside of more than 38%, according to FactSet.

Persons: Eli Lilly, Tesla, Morgan Stanley, Terence Flynn, FactSet, Uber, Stephen Bersey, Bersey Organizations: Dow Jones, Nasdaq, Federal Reserve, CNBC, RSI, pharma, Traders, Uber, Technologies, HSBC Locations: Thursday's, Biogen

☆ Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
▼ + stars: | 2024-01-24 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Lilly's Mounjaro and Zepbound both use tirzepatide as an active ingredient, but Mounjaro is indicated for type 2 diabetes, while Zepbound aids weight loss. A rich valuation LLY 1Y mountain Eli Lilly shares over the past year. But even good news about Zepbound's launch might not be enough to propel Lilly's stock higher. Goldman's Shibutani has a neutral rating on Lilly shares and a price targe of $600, which implies shares could fall nearly 5% from they started the week. He has a buy rating on Lilly shares, and expects the stock could hit $700 over the next 12 months.

Persons: Eli Lilly's, Lilly, Goldman Sachs, Chris Shibutani, IQVIA, Shibutani, Lilly's, Mounjaro, Eli Lilly, Geoff Meacham, NASH, Meacham, there's, Morgan Stanley, Terence Flynn, Flynn, Morgan Stanley's, Michael Bloom Organizations: Food and Drug Administration, Zepbound, Novo Nordisk's, Medicare, Bank of America, Novo Nordisk, Bank of, FDA, CNBC Locations: Indianapolis, Mounjaro

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ Morgan Stanley sees Eli Lilly shares rallying on data showing heart benefit of Novo's obesity drug
▼ + stars: | 2023-08-08 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Danish drugmaker Novo Nordisk 's promising data on its obesity drug Wegovy should benefit Eli Lilly 's pipeline and its stock, according to Morgan Stanley. Shares of Novo Nordisk soared 15% in early trading Tuesday after late-stage trial data showed that Wegovy reduced the risk of major cardiovascular events, such as heart attacks or strokes, by 20%, compared with a placebo. "This is above our expectations and our prior analysis," Morgan Stanley analyst Terence Flynn said. Flynn has an overweight rating on Eli Lilly and a $560 12-month price target, which would translate into a 23% gain from Monday's close of $454.08. Eli Lilly raised its full-year guidance Tuesday as second-quarter profit jumped 85% from the same period a year ago on strong sales resulting from its drug pipeline.

Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's, Flynn, — CNBC's Michael Bloom Organizations: Nordisk, Novo Nordisk Locations: Indianapolis

☆ J&J shares on track for biggest daily drop in 3 years on talc setback
▼ + stars: | 2023-07-31 | by ( ) www.reuters.com time to read: +1 min

Companies Johnson & Johnson FollowJuly 31 (Reuters) - Shares in Johnson & Johnson (JNJ.N) were down 4.1% on Monday and looked set for their biggest one-day percentage loss since June 2020 after a U.S. judge shot down its second attempt to resolve tens of thousands of talc-related lawsuits. Johnson & Johnson has now failed twice to resolve talc suits by offloading the related liabilities into a new company and placing it into bankruptcy. Lawsuits had alleged baby powder and other talc products sometimes contained asbestos and caused mesothelioma, ovarian cancer and other cancers. J&J has said its talc products are safe and do not contain asbestos. Flynn, who rates J&J stock 'equal-weight,' has a $187 price target on the stock compared with the median Wall Street price target of $180, according to Refinitiv which shows 23 analysts covering J&J.

Persons: Johnson, imperils, Morgan Stanley, Terence Flynn, Friday's, Flynn, J, Sinéad Carew, Deepa Babington Organizations: Johnson, Thomson Locations: U.S

☆ Eli Lilly's weight loss drugs trounce sky-high expectations, boosting the stock
▼ + stars: | 2023-06-27 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

What's more, some showed no signs their weight loss was leveling off, suggesting they could continue to shed pounds. (Both use semaglutide, but Ozempic is marketed as a type 2 diabetes treatment, while Wegovy is primarily for weight loss.) Bank of America's Geoff Meacham said retatrutide "exceeded expectations" for weight loss. "This is important, as while the overall 22.4% weight loss was impressive, looking at men and women separately, weight loss was 21.9% and 28.5%, respectively, with the slope in females not yet plateauing. Schott also described the weight loss as "impressive" and said it will likely compare favorably with Novo's next-generation drug CagriSema, which is expected to show weight loss of more than 25% when it releases its next update.

Persons: Eli Lilly, What's, Lilly, Lilly's, Carter Gould, Gould, orforglipron, Bank of America's Geoff Meacham, retatrutide, Meacham, Chris Schott, Schott, Novo's, Evan David Seigerman, Seigerman, Morgan Stanley, Terence Flynn, — CNBC's Michael Bloom Organizations: American Diabetes Association, Wall, Novo Nordisk, Barclays, Bank of America's, JPMorgan, Lilly, BMO Capital, Indianapolis, ~$ Locations: Novo

☆ Johnson & Johnson is the most overbought stock on Wall Street. Here are the others
▼ + stars: | 2023-06-25 | by ( Fred Imbert | ) www.cnbc.com time to read: +3 min

The S & P 500 lost more than 1% for the week, snapping a five-week winning streak. A stock is considered overbought if its 14-day RSI goes above 70, signaling investors should consider easing their exposure. A 14-day RSI under 30, however, signals that a stock is oversold, meaning there may be a buying opportunity. Here's a look at the most overbought stocks in the S & P 500. Johnson & Johnson is the most overbought stock in the index with 14-day RSI of nearly 92.

Persons: Johnson, Morgan Stanley's Terence Flynn, aren't, — CNBC's Michael Bloom Organizations: Airlines Delta, Royal, Akamai Technologies, Enphase Energy, SolarEdge Technologies Locations: U.S, Southwest, Royal Caribbean, DAL

☆ Obesity is a chronic disease. It's why treating it will be so profitable unless payers push back
▼ + stars: | 2023-04-30 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Lilly manufactures tirzepatide, which is sold under the brand name Mounjaro as a type 2 diabetes treatment. It's the chronic nature of obesity that will make these drugs so profitable, analysts have said. Huynh increased his target due to higher expectations for Mounjaro sales this year. Huynh boosted his prediction for the drug's sales this year to $3.7 billion from an prior estimate of $2.7 billion. "$48 billion is a monster number," Holz said, referring to an annual sales estimate that Bank of America has floated for future Mounjaro sales.

☆ Johnson & Johnson shares rise after company proposes baby powder cancer settlement
▼ + stars: | 2023-04-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson shares on Wednesday climbed after the company proposed paying $8.9 billion to settle thousands of claims that its baby powder and other talc products caused cancer. The pharmaceutical giant also said its subsidiary LTL Management refiled for Chapter 11 bankruptcy protection after its first attempt faced legal challenges. JPMorgan analyst Chris Schott on Thursday called the proposed settlement a positive for the company in a note. The proposed $8.9 billion settlement is also in-line with JPMorgan's $8 billion to $10 billion estimate, Schott noted. It's also unclear whether the proposed settlement will win approval in bankruptcy court, Bank of America analyst Geoff Meacham noted Thursday.

Search resuls for: "Terence Flynn"

14 mentions found